Vaccinex Inc. (VCNX)
1.10
-0.04 (-3.51%)
At close: Feb 28, 2025, 11:48 AM
1.34
21.41%
After-hours: Dec 17, 2024, 07:43 PM EST
Vaccinex Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
| Revenue | 570K | 100K | 900K | 50K | 523K | 724K | 90K | 316K |
| Cost of Revenue | n/a | 207K | 169K | 2K | 199K | 1.03M | 160K | 115K |
| Gross Profit | 570K | -107K | 731K | 48K | 324K | -309K | -70K | 201K |
| Operating Income | -22.89M | -19.91M | -22.49M | -28.33M | -32.02M | -27.28M | -21.1M | -20.26M |
| Interest Income | n/a | 2K | 809K | 489K | n/a | n/a | n/a | n/a |
| Pretax Income | -20.25M | -19.82M | -22.38M | -28.85M | -31.86M | -29.52M | -18.76M | -13.94M |
| Net Income | -20.25M | -19.72M | -23.23M | -29.31M | -32.02M | -29.52M | -18.72M | -13.94M |
| Selling & General & Admin | 6.88M | 6.2M | 6.23M | 7.41M | 6.67M | 4.62M | 4.48M | 4.43M |
| Research & Development | 16.57M | 13.98M | 17.16M | 21.55M | 25.67M | 22.35M | 16.55M | 16.03M |
| Other Expenses | n/a | -175K | 43K | -575K | 152K | 165K | -40K | -4K |
| Operating Expenses | 23.45M | 20.01M | 23.39M | 28.38M | 32.34M | 26.97M | 21.03M | 20.46M |
| Interest Expense | 1K | 2K | 809K | 489K | n/a | 392K | 1.36M | 2.99M |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 23.45M | 20.01M | 23.39M | 28.38M | 32.54M | 28M | 21.19M | 20.57M |
| Income Tax | n/a | -93K | 852K | 458K | 152K | -1.84M | 1.28M | 2.99M |
| Shares Outstanding (Basic) | 463.65K | 202.08K | 136.63K | 89.46K | 61.34K | 24.87K | 27.14K | 26.46K |
| Shares Outstanding (Diluted) | 463.65K | 202.08K | 137.38K | 89.46K | 61.34K | 24.87K | 27.14K | 26.46K |
| EPS (Basic) | -43.68 | -97.59 | -170.04 | -327.62 | -521.95 | -1.19K | -689.86 | -526.85 |
| EPS (Diluted) | -43.68 | -97.59 | -169.11 | -327.62 | -521.95 | -1.19K | -689.86 | -526.85 |
| EBITDA | -19.75M | -19.61M | -21.4M | -28.05M | -31.61M | -28.9M | -17.2M | -10.78M |
| Depreciation & Amortization | 119K | 207K | 169K | 307K | 249K | 223K | 206K | 178K |